References
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
- Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11:531–546.
- de Vries AC, Vall Gfieken NC, Looman CW, et al. GC risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:945–952.
- Rugge M, de Boni M, Pennelli G, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther. 2010;31:1104–1111.
- Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007;56:631–636.
- Capelle L, de Vries A, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71:1150–1158.
- Rugge M, Fassan M, Pizzi M, et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. WJG. 2011;17:4596–4601.
- Kudo T, Kakizaki S, Sohara N, et al. Analysis of ABC (D) stratification for screening patients with gastric cancer. World J Gastroenterol. 2011;17:4793–4798.
- Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161–1181.
- Chinese Society of Digestive Endoscopy. Early GC screening program in China. Chin J Dig Endosc. 2014;31:361--377.
- Eybpoosh S, Talebkhan Y, Saberi S, et al. Age-specific gastric cancer risk indicated by the combination of Helicobacter pylori sero-status and serum pepsinogen levels. Iran Biomed J. 2015;19:133–142.
- Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of GC from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54:764–768.
- Daugule I, Sudraba A, Chiu HM, et al. Gastric plasma biomarkers and Operative Link for Gastritis Assessment gastritis stage. Eur J Gastroenterol Hepatol. 2011;23:302–307.
- De Re V, Orzes E, Canzonieri V, et al. Pepsinogens to distinguish patients with gastric intestinal metaplasia and Helicobacter pylori infection among populations at risk for GC. Clin Trans Gastroenterol. 2016;7:e183–e121.
- Cho SJ, Choi IJ, Kook MC, et al. Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems. Aliment Pharmacol Ther. 2013;38:1292–1302.
- Haj-Sheykholeslami A, Rakhshani N, Amirzargar A, et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of GC patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol. 2008;6:174–179.
- Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 2007;8:8–14.
- Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence consensus report. Gut. 2012;61:646–664.
- Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245–253.
- Syrjanen K. A panel of serum biomarkers (GastroPanel®) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. Anticancer Res. 2016;36:5133–5144.